Evidence map›Paper›PMID 37373079›Full record

ArticleInternational journal of molecular sciences2023

New Insights into Immunopathology Associated to

Joel J M Gabrili, Giselle Pidde, Fabio Carlos Magnoli, Rafael Marques-Porto, Isadora Maria Villas-Boas, Carla Cristina Squaiella-Baptistão, Felipe Silva-de-França, François Burgher, Joël Blomet, Denise V Tambourgi

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Thromboinflammatory complications ofFrontiers in immunology · 2025
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Joel J M GabriliImmunochemistry Laboratory, Butantan Institute, São Paulo 05503-900, Brazil.
Giselle PiddeImmunochemistry Laboratory, Butantan Institute, São Paulo 05503-900, Brazil.
Fabio Carlos MagnoliImmunochemistry Laboratory, Butantan Institute, São Paulo 05503-900, Brazil.
Rafael Marques-PortoDevelopment and Innovation Laboratory, Butantan Institute, São Paulo 05503-900, Brazil.
Isadora Maria Villas-BoasImmunochemistry Laboratory, Butantan Institute, São Paulo 05503-900, Brazil.
Carla Cristina Squaiella-BaptistãoImmunochemistry Laboratory, Butantan Institute, São Paulo 05503-900, Brazil.ORCID 0000-0002-4187-798X
Felipe Silva-de-FrançaImmunochemistry Laboratory, Butantan Institute, São Paulo 05503-900, Brazil.
François BurgherPrevor Laboratory, 95760 Valmondois, France.
Joël BlometPrevor Laboratory, 95760 Valmondois, France.
Denise V TambourgiImmunochemistry Laboratory, Butantan Institute, São Paulo 05503-900, Brazil.ORCID 0000-0003-1896-9074
Instituto Butantan · BR

Funding

National Council for Scientific and Technological Development 308390/2021-0
6 · The paper itself

Abstract

The systemic increase in inflammatory mediator levels can induce diverse pathological disorders, including potentially thrombus formation, which may be lethal. Among the clinical conditions in which the formation of thrombi dictates the patient's prognosis, envenomation by

Indexed as

BothropsSnake BitesToxins, BiologicalAnimalsComplement System ProteinsHumansPhospholipases A2Snake VenomsVenomous SnakesComplement System ProteinsPhospholipases A2Snake VenomsToxins, BiologicalBothrops lanceolatuscomplement systeminflammationPLA2snake venom

Identifiers

PMID37373079
PMCPMC10298673
OpenAlexW4380085210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.